Alzheimer’s

The Aduhelm Files Damian Garde and Adam Feuerstein

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

Biotech Jason Mast

For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune

In the Lab Angus Chen

Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s

In the Lab Megan Molteni

In the blood of marathoning mice, scientists find clues to how exercise benefits the brain

Biotech Adam Feuerstein

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

Adam's Take Adam Feuerstein

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

Pharma Adam Feuerstein

In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment

First Opinion Jim Taylor

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

Biotech Matthew Herper and Adam Feuerstein

Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers

Biotech Damian Garde

What to look for in Lilly’s eagerly awaited Alzheimer’s data

Biotech Damian Garde and Adam Feuerstein

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Biotech Matthew Herper

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

Biotech Adam Feuerstein, Damian Garde and Meg Tirrell

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Biotech Matthew Herper, Adam Feuerstein and Damian Garde

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Biotech Damian Garde and Adam Feuerstein

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Pharmalot Ed Silverman

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

Biotech Damian Garde and Adam Feuerstein

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Biotech Adam Feuerstein and Damian Garde

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

Biotech Adam Feuerstein

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

Biotech Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

First Opinion Jason Karlawish

Hospitalized adults need their caregivers — they aren’t visitors

Biotech Damian Garde

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Biotech Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

First Opinion Dennis J. Selkoe

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

In the Lab Sharon Begley

Alzheimer’s

Most Read

European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment

Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions

Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment

Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

All Coverage

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune

Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s

In the blood of marathoning mice, scientists find clues to how exercise benefits the brain

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers

What to look for in Lilly’s eagerly awaited Alzheimer’s data

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Hospitalized adults need their caregivers — they aren’t visitors

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Startup Arkuda targets rapidly advancing, rare form of dementia

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

New prize offers $2 million for finding key to Alzheimer’s in past research

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day